Now, anti-PD-1 antibodies (antiPD1) nivolumab5 and pembrolizumab6 have been approved for the treatment of head and neck cancers and have provided long-term survival to patients with locally advanced and metastatic head and neck cancers. Here, PDCD1 is linked to head and neck cancer.